Noked Capital LTD Takes $211,000 Position in AbbVie Inc (NYSE:ABBV)

Noked Capital LTD bought a new stake in AbbVie Inc (NYSE:ABBV) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,900 shares of the company’s stock, valued at approximately $211,000.

Several other large investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of AbbVie by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 17,582,527 shares of the company’s stock valued at $1,617,957,000 after buying an additional 880,288 shares during the last quarter. grace capital grew its position in AbbVie by 83.3% in the fourth quarter. grace capital now owns 5,500 shares of the company’s stock valued at $507,000 after purchasing an additional 2,500 shares in the last quarter. BT Wealth Management LLC bought a new position in AbbVie in the fourth quarter valued at $1,032,000. Nalls Sherbakoff Group LLC bought a new position in AbbVie in the fourth quarter valued at $83,000. Finally, Kaizen Advisory LLC grew its position in AbbVie by 8.9% in the fourth quarter. Kaizen Advisory LLC now owns 4,151 shares of the company’s stock valued at $383,000 after purchasing an additional 339 shares in the last quarter. Institutional investors own 68.15% of the company’s stock.

In related news, SVP Nicholas Donoghoe bought 7,525 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was purchased at an average cost of $66.19 per share, with a total value of $498,079.75. Following the purchase, the senior vice president now directly owns 13,090 shares of the company’s stock, valued at approximately $866,427.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeffrey Ryan Stewart bought 15,552 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $64.44 per share, with a total value of $1,002,170.88. Following the completion of the purchase, the senior vice president now directly owns 65,304 shares in the company, valued at $4,208,189.76. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 143,077 shares of company stock worth $9,564,951. 0.08% of the stock is owned by corporate insiders.



A number of research firms recently issued reports on ABBV. ValuEngine downgraded shares of AbbVie from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. Piper Jaffray Companies increased their price target on shares of AbbVie from $80.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Goldman Sachs Group started coverage on shares of AbbVie in a research report on Tuesday, May 28th. They set a “neutral” rating and a $84.00 price target for the company. TheStreet lowered shares of AbbVie from a “b-” rating to a “c” rating in a research report on Monday, August 26th. Finally, Leerink Swann upgraded shares of AbbVie to a “buy” rating in a research report on Tuesday, July 2nd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $91.20.

NYSE:ABBV traded down $0.26 during trading hours on Wednesday, hitting $72.69. The company had a trading volume of 136,407 shares, compared to its average volume of 7,542,071. The company has a market capitalization of $107.03 billion, a PE ratio of 9.17, a price-to-earnings-growth ratio of 1.48 and a beta of 0.95. The stock has a 50-day moving average price of $67.35 and a 200 day moving average price of $74.34. AbbVie Inc has a 52 week low of $62.66 and a 52 week high of $96.60.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 26th. The company reported $2.26 EPS for the quarter, beating the consensus estimate of $2.21 by $0.05. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The business had revenue of $8.26 billion during the quarter, compared to analyst estimates of $8.09 billion. During the same quarter last year, the firm posted $2.00 earnings per share. The company’s revenue for the quarter was down .3% on a year-over-year basis. On average, sell-side analysts forecast that AbbVie Inc will post 8.9 EPS for the current fiscal year.

The firm also recently disclosed a — dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $1.07 dividend. This represents a yield of 6.4%. The ex-dividend date is Friday, October 11th. AbbVie’s payout ratio is currently 54.11%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

See Also: Is it better to buy a fund with a higher or lower NAV?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.